The objective of this report is to perform a systematic review of the beneficial and harmful effects of ranolazine 500 mg and 1,000 mg ER tablets as an add-on therapy for the treatment of stable angina pectoris in adults who are inadequately controlled or intolerant to first-line antianginal therapies.
Copyright © 2021 Canadian Agency for Drugs and Technologies in Health.